Role of PKB/Akt in liver diseases

Signaling Pathways in Liver Diseases

Volumn , Issue , 2010, Pages 243-259

  Zhuravleva, Elena ^a   Tschopp, Oliver ^a   Hemmings, Brian A ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79953677340     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-00150-5_16     Document Type: Chapter

References (143)

1. Jones PF, Jakubowicz T, Pitossi FJ et al (1991) Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci U S A 88(10):4171-4175
2. Bellacosa A, Testa JR, Staal SP et al (1991) A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 254(5029):274-277
3. Coffer PJ, Woodgett JR (1991) Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. J Biochem 201(2):475-481
4. Brazil DP, Hemmings BA (2001) Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 26(11):657-664
5. Brazil DP, Yangand ZZ, Hemmings BA (2004) Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 29(5):233-242
6. Fayard E, Tintignac LA, Baudry A et al (2005) Protein kinase B/Akt at a glance. J Cell Sci 118(Pt 24):5675-5678
7. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129(7):1261-1274
8. Haslam RJ, Koideand HB, Hemmings BA (1993) Pleckstrin domain homology. Nature 363(6427):309-310
9. Bellacosa A, Franke TF, Gonzalez-Portal ME et al (1993) Structure, expression and chromosomal mapping of c-akt: relationship to v-akt and its implications. Oncogene 8(3):745-754
10. Altomare DA, Lyons GE, Mitsuuchi Y et al (1998) Akt2 mRNA is highly expressed in embryonic brown fat and the AKT2 kinase is activated by insulin. Oncogene 16(18):2407-2411
11. Yang ZZ, Tschopp O, Hemmings-Mieszczak M et al (2003) Protein kinase B alpha/Akt1 regulates placental development and fetal growth. J Biol Chem 278(34):32124-32131
12. Dahle MK, Overland G, Myhre AE et al (2004) The phosphatidylinositol 3-kinase/protein kinase B signaling pathway is activated by lipoteichoic acid and plays a role in Kupffer cell production of interleukin-6(IL-6) and IL-10. Infect Immun 72 (10):5704-5711
13. Ping C, Xiaoling D, Jin Z et al (2006) Hepatic sinusoidal endothelial cells promote hepatocyte proliferation early after partial hepatectomy in rats. Arch Med Res 37(5):576-583
14. Ping C, Lin Z, Jiming D et al (2006) The phosphoinositide 3-kinase/Akt-signal pathway mediates proliferation and secretory function of hepatic sinusoidal endothelial cells in rats after partial hepatectomy. Biochem Biophys Res Commun 342(3):887-893
15. Wymann MP, Marone R (2005) Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr Opin Cell Biol 17(2):141-149
16. Engelman JA, Luoand J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7(8):606-619
17. Samuels Y, Diaz LA Jr, Schmidt-Kittler O et al (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7(6):561-573
18. Alessi DR, James SR, Downes CP et al (1997) Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7(4):261-269
19. Calleja V, Alcor D, Laguerre M et al (2007) Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. PLoS Biol 5(4):e95
20. Bayascas JR, Wullschleger S, Sakamoto K et al (2008) Mutation of the PDK1 PH domain inhibits protein kinase B/Akt, leading to small size and insulin resistance. Mol Cell Biol 28(10):3258-3272
21. Yang J, Cron P, Thompson V et al (2002) Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol Cell 9(6):1227-1240
22. Sarbassov DD, Guertin DA, Ali SM et al (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712):1098-1101
23. Bhaskar PT, Hay N (2007) The two TORCs and Akt. Dev Cell 12(4):487-502
24. Feng J, Park J, Cron P et al (2004) Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem 279(39):41189-41196
25. Bozulic L, Surucu B, Hynx D et al (2008) PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell 30(2):203-213
26. Jensen MR, Schoepfer J, Radimerski T et al (2008) NVPAUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 10(2):R33
27. Stuhmer T, Zollinger A, Siegmund D et al (2008) Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia 22(8):1604-12
28. Hostein I, Robertson D, DiStefano F et al (2001) Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 61(10):4003-9
29. Sato S, Fujitaand N, Tsuruo T (2000) Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A 97(20):10832-7
30. Laine J, Kunstle G, Obata T et al (2000) The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 6(2):395-407
31. Pekarsky Y, Koval A, Hallas C et al (2000) Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci U S A 97(7):3028-33
32. Remy I, Michnick SW (2004) Regulation of apoptosis by the Ft1 protein, a new modulator of protein kinase B/Akt. Mol Cell Biol 24(4):1493-504
33. Salmena L, Carracedoand A, Pandolfi PP (2008) Tenets of PTEN tumor suppression. Cell 133(3):403-414
34. Horie Y, Suzuki A, Kataoka E et al (2004) Hepatocytespecific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 113(12):1774-83
35. Hu TH, Wang CC, Huang CC et al (2007) Down-regulation of tumor suppressor gene PTEN, overexpression of p53, plus high proliferating cell nuclear antigen index predict poor patient outcome of hepatocellular carcinoma after resection. Oncol Rep 18(6):1417-26
36. Andjelkovic M, Jakubowicz T, Cron P et al (1996) Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proc Natl Acad Sci U S A 93(12):5699-704
37. Ugi S, Imamura T, Maegawa H et al (2004) Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Mol Cell Biol 24(19):8778-89
38. Gao T, Furnariand F, Newton AC (2005) PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18(1):13-24
39. Nawa M, Kanekura K, Hashimoto Y et al (2008) A novel Akt/PKB-interacting protein promotes cell adhesion and inhibits familial amyotrophic lateral sclerosis-linked mutant SOD1-induced neuronal death via inhibition of PP2Amediated dephosphorylation of Akt/PKB. Cell Signal 20(3):493-505
40. Basso AD, Solit DB, Chiosis G et al (2002) Akt forms an intracellular complex with heat shock protein 90(Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 277 (42):39858-39866
41. Brognard J, Sierecki E, Gao T et al (2007) PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 25(6):917-31
42. Liu F, Roth RA (1995) Grb-IR: a SH2-domain-containing protein that binds to the insulin receptor and inhibits its function. Proc Natl Acad Sci U S A 92(22):10287-10291
43. Wang L, Balas B, Christ-Roberts CY et al (2007) Peripheral disruption of the Grb10 gene enhances insulin signaling and sensitivity in vivo. Mol Cell Biol 27(18):6497-505
44. Wick KR, Werner ED, Langlais P et al (2003) Grb10 inhibits insulin-stimulated insulin receptor substrate (IRS) - phosphatidylinositol 3-kinase/Akt signaling pathway by disrupting the association of IRS-1/IRS-2 with the insulin receptor. J Biol Chem 278(10):8460-7
45. Jahn T, Seipel P, Urschel S et al (2002) Role for the adaptor protein Grb10 in the activation of Akt. Mol Cell Biol 22(4):979-91
46. Shiura H, Miyoshi N, Konishi A et al (2005) Meg1/Grb10 overexpression causes postnatal growth retardation and insulin resistance via negative modulation of the IGF1R and IR cascades. Biochem Biophys Res Commun 329(3):909-16
47. Maira SM, Galetic I, Brazil DP et al (2001) Carboxylterminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. Science 294(5541):374-80
48. Paramio JM, Segrelles C, Ruiz S et al (2001) Inhibition of protein kinase B (PKB) and PKC{zeta} mediates keratin K10-induced cell cycle arrest. Mol Cell Biol 21(21):7449-7459
49. Tokuda E, Fujita N, Oh-hara T et al (2007) Casein kinase 2-interacting protein-1, a novel Akt pleckstrin homology domain-interacting protein, down-regulates PI3K/Akt signaling and suppresses tumor growth in vivo. Cancer Res 67(20):9666-76
50. Du K, Herzig S, Kulkarni RN et al (2003) TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 300(5625):1574-7
51. Okamoto H, Latres E, Liu R et al (2007) Genetic deletion of Trb3, the mammalian Drosophila tribbles homolog, displays normal hepatic insulin signaling and glucose homeostasis. Diabetes 56(5):1350-1356
52. Gulati P, Thomas G (2007) Nutrient sensing in the mTOR/S6K1 signalling pathway. Biochem Soc Trans 35(Pt 2):236-8
53. Pende M, Kozma SC, Jaquet M et al (2000) Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature 408(6815):994-7
54. Constantinou C, Clemens MJ (2005) Regulation of the phosphorylation and integrity of protein synthesis initiation factor eIF4GI and the translational repressor 4E-BP1 by p53. Oncogene 24(30):4839-50
55. Fingar DC, Richardson CJ, Tee AR et al (2004) mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24(1):200-16
56. Hara K, Yonezawa K, Kozlowski MT et al (1997) Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem 272(42):26457-63
57. Wang L, Harrisand TE, Lawrence JC Jr (2008) Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1(mTORC1) - mediated phosphorylation. J Biol Chem 283 (23):15619-27
58. Thedieck K, Polak P, Kim ML et al (2007) PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS ONE 2(11):e1217
59. Sancak Y, Thoreen CC, Peterson TR et al (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25(6):903-15
60. Fonseca BD, Smith EM, Lee VH et al (2007) PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J Biol Chem 282(34):24514-24
61. Oshiro N, Takahashi R, Yoshino K et al (2007) The prolinerich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem 282(28):20329-39
62. Vander Haar E, Lee SI, Bandhakavi S et al (2007) Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 9(3):316-23
63. Condorelli G, Drusco A, Stassi G et al (2002) Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci U S A 99(19):12333-8
64. Bernal-Mizrachi E, Wen W, Stahlhut S et al (2001) Islet beta cell expression of constitutively active Akt1/PKB alpha induces striking hypertrophy, hyperplasia, and hyperinsulinemia. J Clin Invest 108(11):1631-8
65. Trumper K, Trumper A, Trusheim H et al (2000) Integrative mitogenic role of protein kinase B/Akt in beta-cells. Ann N Y Acad Sci 921:242-50
66. Graff JR, Konicek BW, McNulty AM et al (2000) Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 275(32):24500-24505
67. Ono H, Shimano H, Katagiri H et al (2003) Hepatic Akt activation induces marked hypoglycemia, hepatomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement. Diabetes 52(12):2905-2913
68. Yang ZZ, Tschopp O, Di-Poi N et al (2005) Dosagedependent effects of Akt1/protein kinase Balpha (PKBalpha) and Akt3/PKBgamma on thymus, skin, and cardiovascular and nervous system development in mice. Mol Cell Biol 25(23):10407-18
69. Cho H, Thorvaldsen JL, Chu Q et al (2001) Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 276(42):38349-52
70. Datta SR, Dudek H, Tao X et al (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91(2):231-41
71. Cardone MH, Roy N, Stennicke HR et al (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282(5392):1318-21
72. Brunet A, Bonni A, Zigmond MJ et al (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96(6):857-68
73. Basu S, Totty NF, Irwin MS et al (2003) Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 11(1):11-23
74. Horvath MM, Wang X, Resnick MA et al (2007) Divergent evolution of human p53 binding sites: cell cycle versus apoptosis. PLoS Genet 3(7):e127
75. Feng J, Tamaskovic R, Yang Z et al (2004) Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation. J Biol Chem 279(34):35510-7
76. Dummler B, Tschopp O, Hynx D et al (2006) Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. Mol Cell Biol 26(21):8042-51
77. Cho H, Mu J, Kim JK et al (2001) Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2(PKB beta). Science 292 (5522):1728-31
78. Garofalo RS, Orena SJ, Rafidi K et al (2003) Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest 112(2):197-208
79. Majewski N, Nogueira V, Bhaskar P et al (2004) Hexokinasemitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 16(5):819-30
80. Cross DAE, Alessi DR, Cohen P et al (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378(6559):785-789
81. McManus EJ, Sakamoto K, Armit LJ et al (2005) Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. Embo J 24(8):1571-83
82. MacAulay K, Doble BW, Patel S et al (2007) Glycogen synthase kinase 3[alpha]-specific regulation of murine hepatic glycogen metabolism. Cell Metab 6(4):329-337
83. Elstrom RL, Bauer DE, Buzzai M et al (2004) Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64(11):3892-9
84. Taniguchi CM, Kondo T, Sajan M et al (2006) Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKC[lambda]/[zeta]. Cell Metab 3(5):343-353
85. Berwick DC, Hers I, Heesom KJ et al (2002) The Identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. J Biol Chem 277(37):33895-33900
86. Bauer DE, Hatzivassiliou G, Zhao F et al (2005) ATP citrate lyase is an important component of cell growth and transformation. Oncogene 24(41):6314-22
87. Yahagi N, Shimano H, Hasegawa K et al (2005) Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer 41(9):1316-1322
88. Gross DN, van den Heuveland AP, Birnbaum MJ (2008) The role of FoxO in the regulation of metabolism. Oncogene 27(16):2320-2336
89. Zhang W, Patil S, Chauhan B et al (2006) FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J Biol Chem 281(15):10105-17
90. Matsumoto M, Pocai A, Rossetti L et al (2007) Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab 6(3):208-16
91. Handschin C, Spiegelman BM (2006) Peroxisome proliferatoractivated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 27(7):728-35
92. Li X, Monks B, Ge Q et al (2007) Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1alpha transcription coactivator. Nature 447(7147):1012-6
93. Zheng X, Yang Z, Yue Z et al (2007) FOXO and insulin signaling regulate sensitivity of the circadian clock to oxidative stress. Proc Natl Acad Sci U S A 104(40):15899-904
94. Clavien PA, Petrowsky H, DeOliveira ML et al (2007) Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 356(15):1545-59
95. Lesurtel M, Graf R, Aleil B et al (2006) Platelet-derived serotonin mediates liver regeneration. Science 312(5770):104-7
96. Michalopoulos GK (2007) Liver regeneration. J Cell Physiol 213(2):286-300
97. Taub R (2004) Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol 5(10):836-47
98. Hong F, Nguyen VA, Shen X et al (2000) Rapid activation of protein kinase B/Akt has a key role in antiapoptotic signaling during liver regeneration. Biochem Biophys Res Commun 279(3):974-9
99. Mullany LK, Nelsen CJ, Hanse EA et al (2007) Akt-mediated liver growth promotes induction of cyclin E through a novel translational mechanism and a p21-mediated cell cycle arrest. J Biol Chem 282(29):21244-52
100. Haga S, Ogawa W, Inoue H et al (2005) Compensatory recovery of liver mass by Akt-mediated hepatocellular hypertrophy in liver-specific STAT3-deficient mice. J Hepatol 43(5):799-807
101. Murata S, Matsuo R, Ikeda O et al (2008) Platelets promote liver regeneration under conditions of Kupffer cell depletion after hepatectomy in mice. World J Surg 32(6):1088-96
102. Jackson LN, Larson SD, Silva SR et al (2008) PI3K/Akt activation is critical for early hepatic regeneration after partial hepatectomy. Am J Physiol Gastrointest Liver Physiol 294(6):G1401-10
103. Angulo P (2007) GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Therap 25(8):883-889
104. Rector RS, Thyfault JP, Wei Y et al (2008) Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 14(2):185-92
105. Piro S, Spadaro L, Russello M et al (2008) Molecular determinants of insulin resistance, cell apoptosis and lipid accumulation in non-alcoholic steatohepatitis. Nutr Metab Cardiovasc Dis 18(8):545-552
106. Samuel VT, Liu Z-X, Qu X et al (2004) Mechanism of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver Disease. J Biol Chem 279(31):32345-32353
107. Mendez-Sanchez N, Arrese M, Zamora-Valdes D et al (2007) Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int 27(4):423-33
108. Lupi R, Del Guerra S, Fierabracci V et al (2002) Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes 51 (Suppl 1): S134-7
109. Joseph JW, Koshkin V, Saleh MC et al (2004) Free fatty acid-induced beta-cell defects are dependent on uncoupling protein 2 expression. J Biol Chem 279(49):51049-56
110. Dyntar D, Eppenberger-Eberhardt M, Maedler K et al (2001) Glucose and palmitic acid induce degeneration of myofibrils and modulate apoptosis in rat adult cardiomyocytes. Diabetes 50(9):2105-2113
111. Li Z, Berk M, McIntyre TM et al (2008) The lysosomalmitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology 47(5):1495-503
112. Rhee SG (1999) Redox signaling: hydrogen peroxide as intracellular messenger. Exp Mol Med 31(2):53-9
113. Leclercq IA, Da Silva Morais A, Schroyen B et al (2007) Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol 47(1):142-56
114. Delibegovic M, Bence KK, Mody N et al (2007) Improved glucose homeostasis in mice with muscle-specific deletion of protein-tyrosine phosphatase 1B. Mol Cell Biol 27(21):7727-34
115. Xue B, Kim YB, Lee A et al (2007) Protein-tyrosine phosphatase 1B deficiency reduces insulin resistance and the diabetic phenotype in mice with polygenic insulin resistance. J Biol Chem 282(33):23829-40
116. Stiles B, Wang Y, Stahl A et al (2004) Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci U S A 101(7):2082-7
117. Vinciguerra M, Sgroi A, Veyrat-Durebex C et al (2009) Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology 49:1176-1184
118. Wang L, Wang WL, Zhang Y et al (2007) Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol Res 37(5):389-396
119. Lee SR, Yang KS, Kwon J et al (2002) Reversible inactivation of the tumor suppressor PTEN by H2O2. J Biol Chem 277(23):20336-42
120. Lee JW, Soung YH, Kim SY et al (2004) PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24(8):1477-1480
121. Tanaka Y, Kanai F, Tada M et al (2006) Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients. Oncogene 25(20):2950-2
122. Villanueva A, Chiang DY, Newell P et al (2008) Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135(6):1972-1983, 1983 e1-e11
123. Nakanishi K, Sakamoto M, Yamasaki S et al (2005) Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 103(2):307-12
124. Tsang TY, Tang WY, Tsang WP et al (2008) Downregulation of hepatoma-derived growth factor activates the Badmediated apoptotic pathway in human cancer cells. Apoptosis 13(9):1135-47
125. Cotler S, Hay N, Xie H et al (2008) Immunohistochemical expression of components of the Akt-mTORC1 pathway is associated with hepatocellular carcinoma in patients with chronic liver disease. Dig Dis Sci 53(3):844-849
126. Baba HA, Wohlschlaeger J, Cicinnati VR et al (2009) Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma. Liver Int 29:399-405
127. Choudhari SR, Khan MA, Harris G et al (2007) Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent Atiprimod. Mol Cancer Ther 6(1):112-121
128. Porstmann T, Griffiths B, Chung YL et al (2005) PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 24(43):6465-81
129. Yang YA, Morin PJ, Han WF et al (2003) Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res 282(2):132-137
130. Pflug BR, Pecher SM, Brink AW et al (2003) Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model. Prostate 57(3):245-54
131. Kuhajda FP (2000) Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16(3):202-208
132. Furuta E, Pai SK, Zhan R et al (2008) Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. Cancer Res 68(4):1003-11
133. Rahman MA, Kyriazanos ID, Ono T et al (2002) Impact of PTEN expression on the outcome of hepatitis C virus-positive cirrhotic hepatocellular carcinoma patients: possible relationship with COX II and inducible nitric oxide synthase. Int J Cancer 100(2):152-7
134. Street A, Macdonald A, Crowder K et al (2004) The hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade. J Biol Chem 279(13):12232-12241
135. Chung YL, Sheuand ML, Yen SH (2003) Hepatitis C virus NS5A as a potential viral Bcl-2 homologue interacts with Bax and inhibits apoptosis in hepatocellular carcinoma. Int J Cancer 107(1):65-73
136. Kim KH, Shin H-J, Kim K et al (2007) Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPAR[gamma]. Gastroenterology 132(5):1955-1967
137. Choi YH, Kim HI, Seong J et al (2004) Hepatitis B virus X protein modulates peroxisome proliferator-activated receptor [gamma] through protein-protein interaction. FEBS Lett 557(1-3):73-80
138. Waris G, Felmlee DJ, Negro F et al (2007) Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J Virol 81(15):8122-30
139. Aytug S, Reich D, Sapiro LE et al (2003) Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 38(6):1384-92
140. Bernsmeier C, Duong FH, Christen V et al (2008) Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. J Hepatol 49(3):429-40
141. Boyault S, Rickman DS, de Reynies A et al (2007) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45(1):42-52
142. Chung T-W, Lee Y-C, Ko J-H et al (2003) Hepatitis B virus X protein modulates the expression of PTEN by inhibiting the function of p53, a transcriptional activator in liver cells. Cancer Res 63(13):3453-3458
143. Kang-Park S, Im JH, Lee JH et al (2006) PTEN modulates hepatitis B virus-X protein induced survival signaling in Chang liver cells. Virus Res 122(1-2):53-60